Cargando…
Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections
Invasive fungal infections cause 1.6 million deaths annually, primarily in immunocompromised individuals. Mortality rates are as high as 90% due to limited treatments. The azole class antifungal, fluconazole, is widely available and has multi-species activity but only inhibits growth instead of kill...
Autores principales: | Wambaugh, Morgan A, Denham, Steven T, Ayala, Magali, Brammer, Brianna, Stonhill, Miekan A, Brown, Jessica CS |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200157/ https://www.ncbi.nlm.nih.gov/pubmed/32367801 http://dx.doi.org/10.7554/eLife.54160 |
Ejemplares similares
-
Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk
por: Lindmark, F, et al.
Publicado: (2005) -
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer
por: Suzuki, H, et al.
Publicado: (2008) -
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity
por: Robey, R W, et al.
Publicado: (2003) -
Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma
por: Gemmill, R M, et al.
Publicado: (2005) -
Five-Feature Model for Developing the Classifier for Synergistic vs. Antagonistic Drug Combinations Built by XGBoost
por: Ji, Xiangjun, et al.
Publicado: (2019)